D
David Valcárcel
Researcher at Autonomous University of Barcelona
Publications - 201
Citations - 4054
David Valcárcel is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 31, co-authored 158 publications receiving 3356 citations. Previous affiliations of David Valcárcel include Hebron University.
Papers
More filters
Journal ArticleDOI
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia
Esperanza Such,Ulrich Germing,Luca Malcovati,José Cervera,Andrea Kuendgen,Matteo G. Della Porta,Benet Nomdedeu,Leonor Arenillas,Elisa Luño,Blanca Xicoy,Mari Luz Amigo,David Valcárcel,Kathrin Nachtkamp,Ilaria Ambaglio,Barbara Hildebrandt,Ignacio Lorenzo,Mario Cazzola,Guillermo Sanz +17 more
TL;DR: The prognostic impact of FAB and WHO subtypes are confirmed, the importance of RBC transfusion dependency and cytogenetics is recognized, and a simple and powerful CPSS is offered for accurately assessing prognosis and planning therapy in patients with CMML.
Journal ArticleDOI
Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival
David Valcárcel,Rodrigo Martino,Dolores Caballero,Jesús Martín,Christelle Ferra,Jose B Nieto,Antonia Sampol,M. Teresa Bernal,José Luis Piñana,Lourdes Vázquez,José M. Ribera,Joan Besalduch,José M. Moraleda,Dolores Carrera,M. Salut Brunet,José A. Pérez-Simón,Jorge Sierra +16 more
TL;DR: The results confirm the capacity of this RIC regimen to obtain long-term remissions in patients ineligible for a conventional allo-SCT and suggest an important role of the development of chronic GVHD in reducing relapse and improving DFS and OS.
Journal ArticleDOI
Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial
José A. Pérez-Simón,Olga López-Villar,Enrique J. Andreu,José Rifón,Sandra Muntión,Maria Diez Campelo,Fermín Sánchez-Guijo,Carmen Martínez,David Valcárcel,Consuelo del Cañizo +9 more
TL;DR: The current study supports the use of the infusion of mesenchymal stem cells expanded using human serum for the treatment of refractory acute or chronic graft-versus-host disease in less heavily treated patients for both acute and chronic transplantation disease.
Journal ArticleDOI
Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/ Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Anna Sureda,Carme Canals,Reyes Arranz,Dolores Caballero,Josep-Maria Ribera,Mats Brune,Jacob Passweg,Rodrigo Martino,David Valcárcel,Joan Besalduch,Rafael F. Duarte,Angel Leon,María Jesús Pascual,Ana García-Noblejas,Lucía López Corral,Bianca Xicoy,Jordi Sierra,Norbert Schmitz +17 more
TL;DR: The HDR-Allo trial as discussed by the authors investigated the potential role of allogeneic stem cell transplantation in this setting and showed that the reduced intensity conditioning approach significantly reduced non-relapse mortality.
Journal ArticleDOI
Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy
Joerg Halter,W. Michael,Michael Schüpbach,Michael Schüpbach,Hanna Mandel,Carlo Casali,Kim Orchard,Matthew Collin,David Valcárcel,Attilio Rovelli,Massimiliano Filosto,Maria Teresa Dotti,Giuseppe Marotta,Guillem Pintos,Pere Barba,Anna Accarino,Christelle Ferra,Isabel Illa,Yves Beguin,Jaap A. Bakker,Jaap Jan Boelens,Irenaeus F.M. de Coo,Keith Fay,Carolyn M. Sue,David Nachbaur,Heinz Zoller,Cláudia Ferreira da Rosa Sobreira,Belinda Pinto Simões,Simon Hammans,David G. Savage,Ramon Martí,Patrick F. Chinnery,Ronit Elhasid,Alois Gratwohl,Michio Hirano +34 more
TL;DR: Allogeneic haematopoietic stem cell transplantation can restore thymidine phosphorylase enzyme function in patients with mitochondrial neurogastrointestinal encephalomyopathy and improve clinical manifestations of mitochondrial neurogeography in the long term.